Satoru Miwa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Satoru Miwa has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Kengo Imai
Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan
5 shared publications- Masanori Mori
Palliative and Supportive Care Division, Seirei Mikatahara General Hospital, Hamamatsu, Japan
5 shared publications Tatsuya Morita
Department of Palliative and Supportive Care, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan
5 shared publicationsToshihiro Yamauchi
Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan
5 shared publicationsSatoshi Inoue
Clinical Laboratory Department, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan
4 shared publicationsAkira Inoue
Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan
3 shared publications
Latest Publications
- 28 July 2026
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 29 (12) , 1704-1710
Is Acute Exacerbation of Terminal Restlessness Predictable Using Continuous Monitoring with a Sheet-Type Nonwearable Sensor Device?
Background: Restlessness is a common and distressing symptom in terminally ill patients with cancer. It is often described as a sudden phenomenon near death; however, its longitudinal progression has not been well characterized. Aim: To examine whether terminal restlessness that worsens suddenly is preceded by changes detectable based on continuous monitoring using a sheet-type nonwearable sensor device. Methods: We conducted secondary analysis of a single-center prospective observational study in a Japanese palliative care unit (2019–2022). The severity of restlessness was measured as activity scores using a sheet-type nonwearable sensor device placed under the mattress. Group-based trajectory modeling was applied to night-time activity scores during the last 30 days of life. Richmond Agitation–Sedation Scale (RASS) scores and medication use were compared across trajectory groups. Results: Of the 1,209 enrolled patients, 959 were included in the final analysis (median age: 75 years, 55% male). A specific patient cluster showing acute exacerbation of terminal restlessness just before death was identified (model-estimated group proportion, 11.1%). In this group, RASS scores and rates of using antipsychotics and benzodiazepines in the final days were significantly higher compared with those in the other groups. Activity scores did not show a sudden increase immediately prior to death; a gradual upward trend was observed beginning approximately two weeks before death, preceding the terminal rise. Conclusion: Approximately 10% of patients experienced exacerbation of terminal restlessness just before death. Continuous monitoring with a non-invasive sensor device may enable earlier detection and prevent exacerbation of terminal restlessness.
- 28 July 2026
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 29 (12) , 1704-1710
Is Acute Exacerbation of Terminal Restlessness Predictable Using Continuous Monitoring with a Sheet-Type Nonwearable Sensor Device?
Background: Restlessness is a common and distressing symptom in terminally ill patients with cancer. It is often described as a sudden phenomenon near death; however, its longitudinal progression has not been well characterized. Aim: To examine whether terminal restlessness that worsens suddenly is preceded by changes detectable based on continuous monitoring using a sheet-type nonwearable sensor device. Methods: We conducted secondary analysis of a single-center prospective observational study in a Japanese palliative care unit (2019–2022). The severity of restlessness was measured as activity scores using a sheet-type nonwearable sensor device placed under the mattress. Group-based trajectory modeling was applied to night-time activity scores during the last 30 days of life. Richmond Agitation–Sedation Scale (RASS) scores and medication use were compared across trajectory groups. Results: Of the 1,209 enrolled patients, 959 were included in the final analysis (median age: 75 years, 55% male). A specific patient cluster showing acute exacerbation of terminal restlessness just before death was identified (model-estimated group proportion, 11.1%). In this group, RASS scores and rates of using antipsychotics and benzodiazepines in the final days were significantly higher compared with those in the other groups. Activity scores did not show a sudden increase immediately prior to death; a gradual upward trend was observed beginning approximately two weeks before death, preceding the terminal rise. Conclusion: Approximately 10% of patients experienced exacerbation of terminal restlessness just before death. Continuous monitoring with a non-invasive sensor device may enable earlier detection and prevent exacerbation of terminal restlessness.
- Open Access
- 1 January 2026
- Published by SAGE Publications in Palliative Medicine Reports
- Vol. 7
Study Protocol for Feasibility Randomized, Placebo-Controlled Trial of Efficacy of Midazolam as the Second-Line Treatment for Dyspnea in Patients with Advanced Cancer
Background: Dyspnea is one of the most distressing symptoms in patients with advanced cancer. Although systemic opioids are recommended as first-line pharmacologic treatment, 30–50% of patients do not achieve adequate relief. Midazolam is often used for persistent dyspnea despite opioid administration; however, robust evidence supporting its efficacy as a second-line treatment remains limited. Objectives: To evaluate the feasibility of a randomized controlled trial assessing the efficacy and safety of continuous subcutaneous midazolam infusion as second-line treatment for persistent dyspnea despite morphine administration in hospitalized patients with advanced cancer. Methods: A protocol for a multicenter, randomized, double-blind, placebo-controlled feasibility trial (J-SUPPORT2201/JORTC-PAL22) is described. The trial is being conducted at nine sites in Japan. Population: Participants are hospitalized adult patients with advanced cancer who are not receiving active anticancer treatment and who experience dyspnea at rest (Integrated Palliative Care Outcome Scale dyspnea score ≥2) despite continuous morphine infusion. Intervention/Control: Protocol treatment includes standardized morphine escalation plus continuous subcutaneous infusion of midazolam (9 or 6 mg/day for vulnerable patients) or placebo for 24 hours. Measurements: The primary endpoint is feasibility, defined as completion of protocol treatment at 24 hours. Secondary endpoints include dyspnea intensity, anxiety, rescue morphine use, communication, adverse events, and 30-day survival. Conclusions: This feasibility trial will provide methodological insights and preliminary clinical data regarding midazolam as a second-line option for persistent dyspnea despite morphine infusion in patients with advanced cancer and help design future confirmatory trials.
- 1 January 2026
- Published by SAGE Publications in Palliative Medicine Reports
- Vol. 7
Open AccessStudy Protocol for Feasibility Randomized, Placebo-Controlled Trial of Efficacy of Midazolam as the Second-Line Treatment for Dyspnea in Patients with Advanced Cancer
Background: Dyspnea is one of the most distressing symptoms in patients with advanced cancer. Although systemic opioids are recommended as first-line pharmacologic treatment, 30–50% of patients do not achieve adequate relief. Midazolam is often used for persistent dyspnea despite opioid administration; however, robust evidence supporting its efficacy as a second-line treatment remains limited. Objectives: To evaluate the feasibility of a randomized controlled trial assessing the efficacy and safety of continuous subcutaneous midazolam infusion as second-line treatment for persistent dyspnea despite morphine administration in hospitalized patients with advanced cancer. Methods: A protocol for a multicenter, randomized, double-blind, placebo-controlled feasibility trial (J-SUPPORT2201/JORTC-PAL22) is described. The trial is being conducted at nine sites in Japan. Population: Participants are hospitalized adult patients with advanced cancer who are not receiving active anticancer treatment and who experience dyspnea at rest (Integrated Palliative Care Outcome Scale dyspnea score ≥2) despite continuous morphine infusion. Intervention/Control: Protocol treatment includes standardized morphine escalation plus continuous subcutaneous infusion of midazolam (9 or 6 mg/day for vulnerable patients) or placebo for 24 hours. Measurements: The primary endpoint is feasibility, defined as completion of protocol treatment at 24 hours. Secondary endpoints include dyspnea intensity, anxiety, rescue morphine use, communication, adverse events, and 30-day survival. Conclusions: This feasibility trial will provide methodological insights and preliminary clinical data regarding midazolam as a second-line option for persistent dyspnea despite morphine infusion in patients with advanced cancer and help design future confirmatory trials.
- Open Access
- 1 January 2026
- Published by SAGE Publications in Palliative Medicine Reports
- Vol. 7
Unfinished Business in Bereaved Families of Patients with Advanced Cancer: Pre–Post QI Evaluation
Background: Unfinished business (UB) and related distress are associated with adverse bereavement outcomes, yet practical strategies remain limited. Objectives: To explore differences in UB-related outcomes across pre- and post-quality improvement (QI) periods. Methods: Pre- and post-QI surveys were conducted among bereaved families of advanced cancer patients at a 27-bed hospice in Japan. The intervention included a one-page pamphlet at admission and clinician attention to prognostic awareness and emotional preparation. Outcomes included the Unfinished Business in Bereavement Scale (UBBS), UB-related distress, and Good Death Inventory domains. Independent samples t -tests with effect sizes (ESs) were used. Results: Valid responses were obtained from 319 pre-QI and 216 post-QI families. UBBS scores (mean 12.46 vs. 11.24; ES = 0.29; p = 0.001) and UB-related distress (4.73 vs. 4.31; ES = 0.25; p = 0.005) were lower, and life completion scores were higher (4.13 vs. 4.50; ES = −0.24; p = 0.007) in the post-QI cohort. Conclusions: The post-QI period was associated with lower UB-related distress, supporting the need for further intervention research.
- 1 January 2026
- Published by SAGE Publications in Palliative Medicine Reports
- Vol. 7
Open AccessUnfinished Business in Bereaved Families of Patients with Advanced Cancer: Pre–Post QI Evaluation
Background: Unfinished business (UB) and related distress are associated with adverse bereavement outcomes, yet practical strategies remain limited. Objectives: To explore differences in UB-related outcomes across pre- and post-quality improvement (QI) periods. Methods: Pre- and post-QI surveys were conducted among bereaved families of advanced cancer patients at a 27-bed hospice in Japan. The intervention included a one-page pamphlet at admission and clinician attention to prognostic awareness and emotional preparation. Outcomes included the Unfinished Business in Bereavement Scale (UBBS), UB-related distress, and Good Death Inventory domains. Independent samples t -tests with effect sizes (ESs) were used. Results: Valid responses were obtained from 319 pre-QI and 216 post-QI families. UBBS scores (mean 12.46 vs. 11.24; ES = 0.29; p = 0.001) and UB-related distress (4.73 vs. 4.31; ES = 0.25; p = 0.005) were lower, and life completion scores were higher (4.13 vs. 4.50; ES = −0.24; p = 0.007) in the post-QI cohort. Conclusions: The post-QI period was associated with lower UB-related distress, supporting the need for further intervention research.
- 19 December 2025
- Published by SAGE Publications in Journal of Palliative Medicine
Body Positioning for Dyspnea in Patients with Cancer with Unilateral Pleural Effusion: A Pilot Trial
Background: Dyspnea is common in advanced cancer, especially with unilateral pleural effusion. Lateral positioning is widely used, but evidence of effectiveness is limited. Objectives: To assess the feasibility and short-term effects of affected-side-down (PLEUR-DOWN) versus affected-side-up (PLEUR-UP) positioning for dyspnea relief. Design: Multicenter randomized crossover pilot trial. Setting/Subjects: Ten patients with cancer with dyspnea were enrolled at seven hospitals in Japan. Methods: Patients (numerical rating scale [NRS] ≥ 3) were randomized to two sequences. Each position was maintained for five minutes within a washout period. The primary outcome was feasibility, assessed by completion, absence of carryover/period effects, and adherence. Secondary outcomes included NRS changes, patient preference, and safety. Results: All patients completed the trial. No significant carryover ( p = 0.57) or period effects ( p = 0.25) were found. Mean NRS difference favored PLEUR-DOWN (−0.9; p = 0.34). Half preferred PLEUR-DOWN. No adverse events occurred. Conclusions: The trial confirmed feasibility and supports further research.
- 19 December 2025
- Published by SAGE Publications in Journal of Palliative Medicine
Body Positioning for Dyspnea in Patients with Cancer with Unilateral Pleural Effusion: A Pilot Trial
Background: Dyspnea is common in advanced cancer, especially with unilateral pleural effusion. Lateral positioning is widely used, but evidence of effectiveness is limited. Objectives: To assess the feasibility and short-term effects of affected-side-down (PLEUR-DOWN) versus affected-side-up (PLEUR-UP) positioning for dyspnea relief. Design: Multicenter randomized crossover pilot trial. Setting/Subjects: Ten patients with cancer with dyspnea were enrolled at seven hospitals in Japan. Methods: Patients (numerical rating scale [NRS] ≥ 3) were randomized to two sequences. Each position was maintained for five minutes within a washout period. The primary outcome was feasibility, assessed by completion, absence of carryover/period effects, and adherence. Secondary outcomes included NRS changes, patient preference, and safety. Results: All patients completed the trial. No significant carryover ( p = 0.57) or period effects ( p = 0.25) were found. Mean NRS difference favored PLEUR-DOWN (−0.9; p = 0.34). Half preferred PLEUR-DOWN. No adverse events occurred. Conclusions: The trial confirmed feasibility and supports further research.
- 12 February 2024
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 67 (5) , 441-452.e3
Comparison of Pharmacological Treatments for Agitated Delirium in the Last Days of Life
- 12 February 2024
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 67 (5) , 441-452.e3
Comparison of Pharmacological Treatments for Agitated Delirium in the Last Days of Life
- 18 April 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 66 (2) , e177-e184
Do Types of Opioids Matter for Terminal Cancer Dyspnea? A Preliminary Multicenter Cohort Study
- 18 April 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 66 (2) , e177-e184
Do Types of Opioids Matter for Terminal Cancer Dyspnea? A Preliminary Multicenter Cohort Study
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 65 (5) , A2-A4
Table of Contents
- 13 April 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 65 (5) , A2-A4
Open AccessTable of Contents
- Open Access
- 19 October 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (5) , 5397-5408
The feasibility and effects of a pharmacological treatment algorithm for cancer patients with terminal dyspnea: A multicenter cohort study
Background: How clinicians treat patients with terminal dyspnea widely varies, which could hamper quality care. We visualized comprehensive pharmacological treatment delivered by palliative care physicians.Aim: To examine adherence to a comprehensive pharmacological treatment algorithm for patients with terminal dyspnea, and to explore its outcomes during 48 h.Design: A multicenter cohort study at five sites (February 2020 to June 2021).Setting/Participants: We prospectively enrolled consecutive patients with advanced cancer, Eastern Cooperative Oncology Group performance status 3–4, and moderate/severe dyspnea. Participating palliative care physicians initiated algorithm‐based treatment. The primary outcome was the proportion of adherence to the treatment algorithm over 24 h (predefined goal, 70%). We evaluated the adherence, goal achievement, and dyspnea level with a numerical rating scale (NRS), as well as adverse events over 48 h.Results: All 108 patients received algorithm‐based pharmacological treatment. Among 96 and 87 patients who were alive at 24 and 48 h, respectively, 96 (100%; 95% confidence interval [CI] = 96%–100%) and 82 (94%; 95%CI = 87%–98%) continued to receive the algorithm treatment, respectively, and 66 (69%; 95%CI = 59%–77%) and 64 (74%; 95%CI = 63%–82%) achieved the treatment goals, respectively. Using a complete case analysis with paired t‐tests, mean dyspnea NRS scores significantly reduced from 7.3 (standard error, 0.2) at the baseline to 4.9 (0.3) at 24 h (n = 72; p < 0.001), and 7.2 (0.3) at the baseline to 4.6 (0.4) at 48 h (n = 55; p < 0.001). Most adverse events were mild to moderate.Conclusions: The comprehensive pharmacological treatment algorithm was feasible, and the study data supports its preliminary efficacy and safety. The use of this algorithm may help clinicians improve care for patients with terminal dyspnea.
- 19 October 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (5) , 5397-5408
Open AccessThe feasibility and effects of a pharmacological treatment algorithm for cancer patients with terminal dyspnea: A multicenter cohort study
Background: How clinicians treat patients with terminal dyspnea widely varies, which could hamper quality care. We visualized comprehensive pharmacological treatment delivered by palliative care physicians.Aim: To examine adherence to a comprehensive pharmacological treatment algorithm for patients with terminal dyspnea, and to explore its outcomes during 48 h.Design: A multicenter cohort study at five sites (February 2020 to June 2021).Setting/Participants: We prospectively enrolled consecutive patients with advanced cancer, Eastern Cooperative Oncology Group performance status 3–4, and moderate/severe dyspnea. Participating palliative care physicians initiated algorithm‐based treatment. The primary outcome was the proportion of adherence to the treatment algorithm over 24 h (predefined goal, 70%). We evaluated the adherence, goal achievement, and dyspnea level with a numerical rating scale (NRS), as well as adverse events over 48 h.Results: All 108 patients received algorithm‐based pharmacological treatment. Among 96 and 87 patients who were alive at 24 and 48 h, respectively, 96 (100%; 95% confidence interval [CI] = 96%–100%) and 82 (94%; 95%CI = 87%–98%) continued to receive the algorithm treatment, respectively, and 66 (69%; 95%CI = 59%–77%) and 64 (74%; 95%CI = 63%–82%) achieved the treatment goals, respectively. Using a complete case analysis with paired t‐tests, mean dyspnea NRS scores significantly reduced from 7.3 (standard error, 0.2) at the baseline to 4.9 (0.3) at 24 h (n = 72; p < 0.001), and 7.2 (0.3) at the baseline to 4.6 (0.4) at 48 h (n = 55; p < 0.001). Most adverse events were mild to moderate.Conclusions: The comprehensive pharmacological treatment algorithm was feasible, and the study data supports its preliminary efficacy and safety. The use of this algorithm may help clinicians improve care for patients with terminal dyspnea.